The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients
Status:
Suspended
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Hypothesis:
Intraperitoneal tPA and DNase is well tolerated at a number of different doses. Different
doses of tPA and DNase will have a dose-related effect on inflammatory markers (CRP and
intraperitoneal white cell count).
Aims:
1. To examine the tolerability of different doses of intraperitoneal tPA and DNase compared
to standard treatment.
2. To examine the changes in biochemical and clinical outcomes of PD Peritonitis with the
addition of intraperitoneal tPA and DNase to usual therapy.